review see Ref. 23) . To carry out their dual functions, the membrane ATPases move via vesicles between intracellular compartments. This means that their transport activity and trafficking must be regulated. Mutations in the genes encoding ATP7A and ATP7B cause human diseases of copper deficiency (Menkes disease) and copper toxicity (Wilson disease), respectively.
Human ATP7B and ATP7A are 60% identical at the amino acid level and share a common topology, with ϳ650-amino acid cytoplasmic NH 2 termini, followed by 8 transmembrane domains, within which lie 2 major cytoplasmic loops that constitute signature domains of P-type ATPases, and ϳ90-amino acid cytoplasmic COOH termini (Fig. 1 ). The NH 2 termini contain six metal-binding domains that are thought to regulate the transport and trafficking functions of these ATPases. Of the Ͼ300 Wilson disease-causing mutations, those disrupting copper transport activity (i.e., mutations/deletions in the P-type ATPase domains) have been largely validated. However, the effects on copper transport of mutations outside these regions, particularly those in the most distal NH 2 and COOH termini, are less obvious. These two regions often encode sequences involved in targeting membrane proteins to their sites of function (3, 4, 6, 28, 32) .
The general trafficking patterns of the two Cu-ATPases are known, although important details and mechanisms remain undefined. When Cu levels are low, both proteins are present in a TGN subcompartment marked by the protein syntaxin 6. When Cu(I) levels are elevated, both proteins exit this compartment in distinct vesicles; those carrying ATP7B are larger than those carrying ATP7A (13, 25) . Furthermore, in polarized epithelia, the ATP7B vesicles traffic to the apical region, whereas the ATP7A vesicles move to the basolateral region. We do not know the extent to which these vesicles fuse with their respective membrane and export Cu(I) directly or first sequester Cu(I) and then release their contents into the apical (ATP7B) and basolateral (ATP7A) environments.
Signals responsible for the targeted trafficking of ATP7B and ATP7A are being identified. Results of mutagenesis studies indicate that the presence of metal-binding domain 5 or 6 and ATPase-dependent Cu(I) transport activity are required, suggesting the importance of specific conformations for trafficking (for review see Refs. 22 and 23, but see Ref. 27 ). Other signals include 1) a nine-amino acid sequence in the NH 2 terminus of ATP7B, which is essential for the protein's retention in the Golgi (ϪCu) and targeting to the apical region in polarized hepatic cells (ϩCu) (5); 2) di-and trileucines (triL) in the COOH termini of ATP7A (11) and ATP7B (8) , respectively, which are required for retrograde trafficking to the Golgi (ϪCu) and basolateral targeting of ATP7A in polarized Madin-Darby canine kidney cells (12) ; and 3) a PDZ-binding motif in the COOH terminus of ATP7A that targets/retains it to/at the basolateral membrane in polarized Madin-Darby canine kidney cells (12) . These studies have established important motifs for the copper-regulated trafficking of ATP7A and ATP7B; however, further investigation is necessary for a more complete understanding of the role(s) played by the NH 2 and COOH termini of these proteins.
Six Wilson disease-associated missense and three premature stop mutations have been identified in the COOH terminus of ATP7B, indicating that this region has significant structural and/or regulatory roles. Each mutation is listed in the Wilson Disease Patient Mutation Database (http://www.wilsondisease-.med.ualberta.ca/database.asp). In the present study, we introduced these mutations into green fluorescent protein (GFP)-ATP7B and examined their effects on protein expression, transport function, and copper-responsive trafficking in a polarized hepatic cell line (WIF-B). Of the six missense mutations, only the two (L1373P and L1373R) located at the junction of transmembrane domain 8 and the COOH-terminal cytoplasmic domain exhibited abnormal behavior in our assays. They were unstable, failed to be retained in the Golgi in low copper, and did not respond to the addition of copper. In contrast, all three premature stop mutations showed relatively normal Golgi retention when kept in low copper and wild-type outward (anterograde) trafficking in elevated copper but were unable to return to the Golgi when copper levels were subsequently depleted (defective retrograde trafficking). We further explored the role of the COOH terminus of ATP7B in trafficking by exchanging it for that of ATP7A. When copper levels were raised, this 7B/7A chimera trafficked to both plasma membrane domains, indicating the presence of a basolateral targeting signal in ATP7A that is absent in ATP7B. Surprisingly, the chimera exhibited a low copper sensitivity and Golgi retention behavior similar to that of wild-type ATP7A (wtATP7A). Finally, our results demonstrating that four Wilson disease-associated missense mutations behave in a wildtype manner in all our assays raise the possibility that they may not be disease-causing mutations.
MATERIALS AND METHODS

Generation of ATP7B Mutations
Generation of full-length wild-type GFP-ATP7B (GFP-wtATP7B; catalog designation pYG7) in pAdLOX (14) is described elsewhere (13) . The QuickChange II XL Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) was used, with pYG7 as a template to create plasmids designated pYGs 24, 68, 65R, and 66R; pFLs 1, 2, 3, and 5; and pLBs 1086, 1089, and 1095. Each encodes GFP at the NH 2 terminus, and the mutation each carries is listed in Supplemental  Table S1 (see Supplemental Material for this article, available online at the Journal website). All primers were obtained from Integrated DNA Technologies (Coralville, IA); their sequences are available upon request. Sequences of all mutated regions in each construct were verified.
To engineer GFP-ATP7B encoding the ATP7A COOH terminus, we used a two-step protocol to swap the ATP7B COOH terminus for the ATP7A COOH terminus. 1) Two regions of ATP7A cDNA encoding amino acids 1407-1500 and 1414 -1500 were amplified using primers that also had flanking sequences homologous to the recipient ATP7B plasmid pYG7.
2) The gel-purified PCR products were used as primers to replace the corresponding region in pYG7 using the QuickChange II XL Site-Directed Mutagenesis kit. The constructs pLB1082-5 and pLB1083 (see Supplemental Table S1 ) had different junctions encoding amino acids 1-1373/1407-1500 and 1-1379/1414 -1500 of ATP7B and ATP7A, respectively. Sequencing confirmed the correct junction in both constructs.
GFP-ATP7A (catalog designation pYG17c) in pAdLOX was generated using four subcloning steps. The final construct was sequenced, revealing a K at residue 1350, which is a normal variant in humans (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rsϭ4826245). The original clone was a gift from B. Eipper (University of Connecticut).
All constructs were packaged into adenoviruses and purified as described elsewhere (2) . To verify that packaged viruses were not Fig. 1 . Schematic of human green fluorescent protein (GFP)-ATP7B domains and COOHterminal sequence (top) and multiple species alignments of ATP7B and ATP7A COOH termini (bottom). Top: metal-binding domains (MBD) 1-6 and transmembrane domains (TMD) 1-8. ATP7B COOH-terminal sequence (L1371-I1465) is enlarged (between arrows), and missense mutations (large font), sites of nucleotide change/insertion/deletions, resulting in truncations ‫,)ء(‬ and trileucine (underlined) are indicated. Bottom: alignments obtained using ClustalW. Residues that are identical ‫,)ء(‬ conserved (:), and semiconserved (.) are shown. Predicted secondary structures of wild-type (wt) ATP7B and wtATP7A COOH termini were obtained using PredJ. Underlined residues are predicted to be ␤-sheets, and underlined and italicized residues are predicted to be ␣-helices.
cross-contaminated, adenoviral DNA was purified from infected 293A cell pellets (14) , three critical regions of ATP7B were PCR-amplified using the purified DNA as template, and the products were sequenced. Amplified region 1 (primer pair 53/444) encoded amino acids 1-166, region 2 (primer pair 47/515) encoded amino acids 429 -704, region 3 short (primer pair 514/41) encoded amino acids 1363-1465, and region 3 long (primer pair 49/41) encoded amino acids 809 -1465. All sequencing was performed by the Johns Hopkins University DNA Sequencing Facility.
Cell Culture and Adenoviral Infection
Two immortalized derivatives of SV40-transformed Menkes-null fibroblasts, designated YS and YSTT, were cultured as previously described (5, 13) . For steady-state half-life studies, YS cells were seeded in 10-cm tissue culture dishes containing six glass coverslips (22 ϫ 22 mm) and used for adenovirus infection 2 or 3 days later (plating density ϭ 1.5 ϫ 10 6 and 7.5 ϫ 10 5 , respectively). Cells on coverslips were transferred to 35-mm dishes and incubated in basal medium (0.3 M Cu) with virus for 1 h and then cultured overnight in basal medium. Low-to-moderate expression in ϳ70 -90% of the cells and high expression in 10 -30% of the cells were obtained when 0.3-4 ϫ 10 9 viral particles were applied per coverslip. WIF-B cells were seeded at 2 ϫ 10 4 cells/cm 2 on glass coverslips (22 ϫ 22 mm), cultured as described elsewhere (7, 18) , and used ϳ11-12 days later, when maximal polarity had been achieved. WIF-B cells were infected as previously described (5), except infections were for 0.5 h and the infected cells were cultured overnight in basal medium alone or with 10 M bathocuproine disulfonic acid (BCS).
Initial Characterization
Tyrosinase activation. Each ATP7B construct was tested for its Cu(I) transport activity in YSTT cells cotransfected with the construct and apotyrosinase and assayed 24 h later, as previously described (5, 13) .
Protein expression. YS, YSTT, or WIF-B cells grown on coverslips were infected with recombinant adenovirus, cultured for 16 -24 h in basal medium, rinsed in PBS, scraped into urea-SDS sample buffer (20 mM Tris·HCl, pH 8.8, 5% SDS, 0.1 M DTT, 15% sucrose, 2 mM EDTA, and 5 M urea), and processed as described elsewhere (13) . Samples were analyzed by SDS-PAGE as described elsewhere (13) or using Nu-PAGE gels (Invitrogen, Carlsbad, CA). After transfer to nitrocellulose, membranes were incubated with anti-ATP7B (5) or anti-GFP (from M. Iijima and P. Devreotes, Johns Hopkins University) diluted in Blocking Buffer (LI-COR Biosciences, Lincoln, NE) and then with goat anti-rabbit IRDye 800cw diluted in PBS containing 0.1% Tween 20. An infrared imaging system (Odyssey, LI-COR Biosciences) was used to visualize protein bands. Alternatively, goat anti-rabbit horseradish peroxidase was used, and the protein bands were visualized by chemiluminescence using the Versa-Doc imaging system (Bio-Rad, Richmond, CA).
Copper-Responsive Trafficking Assays
BCS ¡ Cu. At 16 -24 h after infection, WIF-B cells cultured in 10 M BCS were rinsed; then one set was fixed (ϩBCS), and a duplicate set was incubated for 1 h in 10 M CuCl 2 (BCS ¡ Cu). Cells were fixed and processed for indirect immunofluorescence according to previously published methods (17) .
Cu ¡ BCS. At 16 -24 h after infection, YS cells cultured in basal medium were treated with 100 M CuCl 2 for a total of 4 h, with the protein synthesis inhibitor cycloheximide (75 g/ml) added during the last 2 h. One set of infected cells (ϩCu) was fixed, and a parallel set (Cu ¡ BCS) was rinsed twice in 100 -200 M BCS ϩ inhibitor and cultured for another 4 -7.5 h, with the inhibitor added after 2-3 h. In preliminary experiments, we determined that this concentration of cycloheximide inhibited incorporation of [
35 S]methionine/cysteine (NEB, Promix) into cellular proteins by Ͼ95% compared with untreated cells (unpublished results). Indirect immunofluorescence. Primary antibodies used for microscopy were as follows: mouse anti-TGN38 from BD Biosciences (San Jose, CA); rabbit anti-aminopeptidase N (no. 1637) and anti-ATP7B (no. 3985) (1, 5) and mouse anti-lysosomal-associated membrane protein 1 (LAMP1) from Iowa Hybridoma Bank; rabbit anti-mannose 6-phosphate receptor (no. 8310) from Dr. Fred Gorelick (Yale University, New Haven, CT); and mouse anti-golgin 97 from Invitrogen. Secondary antibodies (at 1.5-4 g/ml) conjugated to Cy3 or Cy5 were obtained from Jackson ImmunoResearch Laboratories (West Grove, PA), and those conjugated to Alexa 488 were obtained from Invitrogen.
Labeled WIF-B cells were analyzed using a ϫ100 plan apochromat, 1.4 numerical aperture oil immersion objective on a confocal microscope (LSM 510 META, Zeiss). We focused on cells that expressed low levels of exogenous protein and assessed the distribution of the GFP relative to distribution of the two organelle markers, TGN38 and aminopeptidase N. Experiments were repeated Ն2 times, and images of 8 -20 cells were evaluated per experiment. Labeled YS cells were analyzed by confocal microscopy or a ϫ40 plan apochromat, 1.4 numerical aperture oil immersion objective on a fluorescence microscope (Axiovert 200M, Zeiss). Images of 10 -25 cells were acquired using Volocity software (Perkin Elmer, Waltham, MA) and evaluated as described above.
Steady-State Half-Life Studies
The protein half-lives of selected constructs were determined using YS cells. Infected cells were treated for 6 h with cycloheximide in basal medium containing 10 mM HEPES, pH 7.5. At selected times, cells on duplicate coverslips were quickly rinsed with PBS and scraped into urea sample buffer as described elsewhere (13) . Immunoblotting was used for analysis of 5-15% of the sample (see below). Infection efficiency and localization patterns were monitored in cells on parallel coverslips fixed at 0, 3, and 6 h and viewed by fluorescence microscopy (see above). Each experiment was repeated at least three times.
Inhibitors. The following inhibitors were used to assess the roles of proteasomes and lysosomes in the degradation of selected GFP-ATP7B constructs: lactacystin (5 M), MG132 (10 M), leupeptin (250 M), pepstatin (10 g/ml), and E64d (10 g/ml); all were obtained from Sigma-Aldrich (St. Louis, MO). Combinations of reagents were added to infected YS cells for up to 6 h in the continuous presence of cycloheximide and then prepared for SDS-PAGE and immunoblotting.
Molecular chaperone. Immediately after infection of a GFP-ATP7B construct, 2 mM 4-phenylbutyric acid was added to WIF-B cells in basal medium. After 24 or 48 h, infected cells were placed in fixative, immunolabeled, and viewed by confocal microscopy as described above.
Immunoblotting. Samples were analyzed by SDS-PAGE using Nu-PAGE gels (Invitrogen) and immunoblotting. The nitrocellulose membranes were incubated first with anti-ATP7B or anti-GFP and then with secondary antibody (see Protein Expression), and the signals were acquired using Odyssey and quantitated using the company's software. The membranes were then incubated with mouse anti-GAPDH clone 6C5 (Fitzgerald Industries, Acton, MA), and secondary antibody was imaged again. For each experiment, duplicate samples were loaded twice. Values at each time point were normalized to the levels of GAPDH present and expressed as a fraction of time 0, which was set to 1. The values from a single experiment were averaged, that value was averaged with those from each experiment, and the standard error of the mean was calculated.
RESULTS
The COOH Terminus of ATP7B Is Highly Conserved and Shares Similarities and Differences With the COOH Terminus of ATP7A
The potential for structural and/or regulatory information within the COOH terminus of ATP7B is strengthened by the presence of putative disease-causing mutations, three of which result in different COOH-terminal truncations and six in single amino acid changes (Fig. 1) . To evaluate the significance of each mutation, we performed an amino acid sequence alignment of the cytosolic COOH-terminal region of ATP7B. We found high sequence conservation among human ATP7B and the dog, sheep, rat, and mouse homologs, with amino acid identities of 87, 82, 83, and 84%, respectively (Fig. 1) . Three of the five residues with missense mutations (L1373, C1375, and P1379) are conserved among these species.
We also compared the ATP7A and ATP7B COOH termini across multiple species. The two COOH termini are similar in length (ϳ95 amino acids) and predicted secondary structure, each having two predicted ␣-helices and ␤-strands in similar positions (Fig. 1) . However, sequence conservation is limited to three regions: 1) adjacent to transmembrane domain 8, the location of several Wilson disease-associated mutations; 2) between residues 1398 and 1410 (the first predicted ␣-helix); and 3) the di-/triL motif near the COOH terminus. A striking difference is the presence of a PDZ-binding motif at the terminus of ATP7A, which is absent from ATP7B; its importance in ATP7A targeting/retention has been reported, and a binding partner has been identified (12, 29) .
Features of GFP-ATP7B Mutant Proteins
As a test of the capacity of the expressed GFP to transport copper into the Golgi, each cDNA construct was transfected, along with a plasmid encoding apotyrosinase, into YSTT fibroblast cells. This line was derived from cells (YS) established from a Menkes patient and, therefore, lacks active ATP7A (5, 13) . At 16 -24 h after transfection, cells were fixed and assayed for the tryosinase-dependent conversion of l-DOPA to DOPA-chrome, which precipitates as a black reaction product that can be visualized by phase microscopy. Negative (no ATP7B construct added) and positive (wtATP7B added) controls were performed in parallel to ensure the specificity of the assay. As shown in Table 1 , all constructs were able to activate tyrosinase, although L1373R was only weakly active.
After packaging the constructs into adenoviruses, we evaluated each protein for its expression and size. Results of SDS-PAGE and immunoblotting of cell lysates from infected YS cells, YSTT fibroblasts, or WIF-B hepatic cells (see Supplemental Fig. S1 ) demonstrated that GFPs with missense mutations or the ATP7A COOH terminus had mobilities similar to that of GFP-wtATP7B (ϳ195 kDa), while those with COOHterminal truncations migrated somewhat faster. Only GFP-L1373R-ATP7B was consistently expressed at low levels.
GFP-ATP7B With an ATP7A COOH Terminus Exhibits Copper-Responsive Trafficking Different From That of GFPwtATP7B
We first determined whether swapping the entire COOH terminus of ATP7A with that of ATP7B had an effect on the copper-responsive trafficking of ATP7B, which was otherwise wild-type. As controls for interpretation of results obtained with the 7B/7A chimeras, we compared the copper-responsive trafficking of GFP-wtATP7B and GFP-wtATP7A in polarized WIF-B cells. In copper-depleted cells, both proteins were restricted to the Golgi ( Figs. 2A and 3A) . GFP-ATP7B-expressing cells treated with 10 M copper for 1 h showed significant redistribution of the protein from the Golgi into vesicles in the apical region and the apical membrane (Fig. 2B) . Incubation of cells with 50 M copper gave a similar pattern (Fig. 2C) . We found no ATP7B signal at the basolateral membrane. These results confirm those we reported earlier (5, 13) . In contrast, cells expressing GFP-wtATP7A and treated similarly showed a less robust redistribution; at 10 M copper, the signal was detected near and in the basolateral membrane, but significant amounts of GFP-wtATP7A were present in the Golgi (Fig. 3B ).
Higher copper concentrations (50 M) were required to observe significant dispersion of GFP-wtATP7A (Fig. 3C) . Importantly, we detected no ATP7A signal at the apical membrane in 10, 50, or 100 M copper. We next determined if the expressed proteins could be returned to the Golgi when copper levels were lowered. To assess retrograde trafficking, we needed to inhibit new protein Fig. 3 . GFP-wtATP7A redistributes from the TGN to the basolateral membrane when copper levels are elevated and returns when levels are lowered. A-C: infected WIF-B cells were treated and processed as described in Fig. 2 legend and then imaged by confocal microscopy. Single confocal planes are shown. Note absence of signal at the apical membrane in all conditions and presence of signal remaining in the TGN at 10 and 50 M CuCl2. n, Nucleus; ‫,ء‬ apical space; Ͼ, basolateral membrane. D and E: infected YS cells were treated and processed as described in Fig. 2 legend and then imaged by confocal microscopy. GFP-wtATP7A returned to the Golgi (4 h) when copper levels were lowered. synthesis, so that only preexisting molecules were visualized. Because the current lineage of WIF-B cells is particularly sensitive to cycloheximide, we developed a retrograde trafficking assay using YS cells (see MATERIALS AND METHODS). GFPwtATP7B and GFP-wtATP7A individually expressed in cells treated with cycloheximide returned to the Golgi when copper levels were lowered (Fig. 2, D and E, and Fig. 3, D and E) .
Having established that the two wild-type Cu-ATPases responded to changes in copper levels by relocalizing to opposite membrane domains in polarized WIF-B cells, we characterized the copper-responsive behavior of the 7B(1373)7A chimera. In copper-depleted WIF-B cells, the protein was restricted to the Golgi (Fig. 4A) . However, unlike either Cu-ATPase in elevated copper, the chimera relocated to both plasma membrane domains of polarized WIF-B cells. Surprisingly, incubation with 10 M copper for 1 h resulted in most of the chimeric protein remaining in the Golgi (data not shown). Treatment of cells with 50 or 100 M copper for 1 h was needed to observe a significant reduction in the Golgi signal (Fig. 4B) . Thus the 7B(1373)7A chimera exhibited low copper sensitivity and Golgi retention behavior similar to that of GFP-wtATP7A.
We used YS cells to test the chimera's ability to return to the Golgi when copper levels were lowered. Figure 4C shows a significant reduction in the chimera signal in the Golgi when cycloheximide was included in the high-copper (100 M) step. When cells were treated with BCS in the continued presence of cycloheximide, the chimeric protein returned to the Golgi (Fig. 4C) .
Deletion of up to the Last 62 Residues of GFP-ATP7B Leads to Loss of Copper-Responsive Retrograde Trafficking
We next determined the protein phenotypes of three patient mutations and one engineered mutation that result in COOHterminal truncations of ATP7B ( Fig. 1 ; see Supplemental Table   Fig. 4 . GFP-ATP7B with an ATP7A COOH terminus exhibits bipolar copper-responsive trafficking. A and B: polarized WIF-B cells infected with GFP-7B(1373)7A were treated and processed as described in Fig. 2 legend and then imaged by confocal microscopy. Single planes are shown. Note presence of signal at apical and basolateral membranes in 50 M CuCl2 and some signal remaining in the TGN. n, Nucleus; ‫,ء‬ apical space; arrow, apical membrane; Ͼ, basolateral membrane. C and D: YS cells infected with GFP-7B(1373)7A were treated and processed as described in Fig. 2 legend and then imaged by confocal microscopy. Chimera returned to the Golgi (4 h) when copper levels were lowered. S1). All these proteins exhibited similar trafficking behavior in hepatic cells (Table 1) . In low copper, there was some variability in their degree of Golgi retention. That is, they could be found in vesicles just outside the Golgi region. We designated this pattern "Golgi retention-deficient." We focused primarily on the dynamics of GFP-Q1399Rfs-ATP7B, because it had the largest deletion of 62 residues and exhibited the greatest deficiency in Golgi retention in BCS (Fig. 5A) . Some of these vesicles overlapped with the TGN/late endosome marker mannose 6-phosphate receptor (unpublished observations). When copper levels were raised to 10 M, all mutant proteins exhibited a wild-type response. That is, they were found in vesicles located between the Golgi and the apical membrane, at the membrane, and in the periphery (Fig. 5B) .
Since all the deletion mutants exhibited relatively normal copper-responsive forward trafficking, as well as the ability to transport copper, we reasoned that the step that could eventually cause the disease phenotype might be associated with protein return to the Golgi. Consequently, we examined the retrograde trafficking behavior of the COOH-terminal truncated ATP7B proteins using YS cells. As shown in Fig. 5 , C and D, GFP-Q1399Rfs-ATP7B protein was dispersed in small vesicles in high copper (Fig. 5C ) but failed to return to the Golgi when copper levels were decreased (Fig. 5D) . The other COOH-terminal truncated ATP7B proteins showed the same defective behavior (Table 1) .
Since all truncation mutants lacked the ATP7B triL motif, which has been implicated in retrograde trafficking, we wondered whether mutation of this motif to trialanine (triA) in the context of full-length GFP-ATP7B (designated triLϾA) would reproduce the copper-responsive behavior of the truncation mutants. Surprisingly, it did. In infected WIF-B cells incubated in BCS, the GFP-triLϾA-ATP7B protein exhibited a more modest deficiency in Golgi retention than did the truncation Fig. 5 . Severely truncated GFP-Q1399Rfs-ATP7B protein exhibits a complex phenotype. A and B: polarized WIF-B cells infected with the GFP-Q1399Rfs-ATP7B adenovirus were treated and processed as described in Fig. 2 legend and then imaged by confocal microscopy. Single planes are shown. In BCS, note presence of the mutant protein in the Golgi, as well as outside. n, Nucleus; ‫,ء‬ apical space; arrow, apical membrane. C and D: YS cells infected with GFP-Q1399Rfs-ATP7B were treated and processed as described in Fig. 2 legend and then imaged by confocal microscopy. Truncated protein failed to return to the Golgi (4 h) when copper levels were lowered. mutants and normal anterograde trafficking behavior in 10 M copper (Table 1 ; see Supplemental Fig. S2 ). However, in YS cells, GFP-triLϾA-ATP7B failed to return to the Golgi when copper levels were lowered. Thus the protein phenotype of GFP-triLϾA-ATP7B closely paralleled those of the truncated ATP7B proteins, raising a question about the role played by residues 1399 -1454 of ATP7B.
Two COOH-Terminal Wilson Disease-Associated Missense Mutations Alter GFP-ATP7B Trafficking and Stability
We next evaluated the protein phenotypes of six GFP-ATP7B constructs with disease-associated missense mutations. Four missense mutations, C1375S, P1379S, T1434M, and X1466R (Table 1) , exhibited trafficking behavior in polarized WIF-B cells similar to that observed for GFP-wtATP7B (see T1434M in Supplemental Fig. S3 ). That is, they exhibited a tight Golgi pattern in low copper (10 M BCS) and redistributed into vesicles in 10 M copper. In YS cells, the four mutant proteins returned to the Golgi when copper levels were lowered (see T1434M in Supplemental Fig. S3 ).
Of the four missense mutants described above, only T1434 is not conserved in ATP7B, whereas C1375 is conserved in ATP7B and P1379 is conserved in both Cu-ATPases. Thus, unlike the distal two-thirds of the COOH terminus of ATP7B, the conserved region closer to the membrane appeared to be less important for retrograde trafficking, perhaps playing another role. Characterization of mutations of the conserved L1373 gave a glimpse into the role of this region.
The missense mutation L1373R exhibited less protein on a Western blot, suggesting an effect on protein stability/degradation (see Supplemental Fig. S1 ). This possibility was confirmed by turnover analysis of the two L1373 mutant proteins relative to that of GFP-wtATP7B (Fig. 6, A and B) . We found the half-lives of both mutant proteins to be significantly shorter than that of GFP-wtATP7B: ϳ3 h for L1373P and ϳ1 h for L1373R vs. ϳ8 h for GFP-wtATP7B.
Both L1373 mutants also exhibited abnormal trafficking behavior. L1373P, the more stable molecule, was found predominantly as a green haze throughout the WIF-B cytoplasm, as well as in vesicles, but not in the Golgi, when copper levels were depleted (Fig. 7A) . Addition of copper did not dramatically alter the protein's distribution (Fig. 7B) . The GFP pattern overlapped very little with a marker of the prelysosomal compartment and not at all with that of the lysosomes (see Supplemental Fig. S4A ), two compartments located in the same region as the mutant protein. L1373P was also found at the apical surface (Fig. 7) in BCS and 10 M copper. The L1373R protein showed similar behavior (Table 1) . When these mutant proteins were expressed in YS cells in basal medium, they localized to the nuclear rim, a pattern indicative of the endoplasmic reticulum (ER; see Supplemental Fig. S4B ). Examination of infected YS cells cultured for 3-6 h in basal medium containing cycloheximide showed a decrease in the (presumed) ER signal but persistence in vesicles (see Supplemental Fig.  S4B ). These results suggest that mutation of L1373 to L1373R or L1373P in ATP7B slowed the proteins' exit from the ER and perturbed their retention in the Golgi under low copper conditions.
The decreased stability and intracellular pattern suggest that mutant protein might have been degraded in the ER, although Fig. 6 . L1373P/R mutant proteins are unstable. A-C: YS cells were infected with the indicated GFP-ATP7B adenovirus and cultured overnight in basal medium. A and B: at time 0, cells on coverslips were harvested into urea sample buffer or switched to medium containing cycloheximide. Duplicate coverslips were harvested 1, 2, 3, 4, and 6 h later and analyzed. A: representative immunoblots of GFP-ATP7B proteins and GAPDH. B: amounts of 3 GFP-ATP7B proteins remaining at each time point relative to normalized quantity detected at time 0. Half-lives are as follows: ϳ7 h for wtATP7B (n ϭ 4), ϳ2-3 h for L1373P (n ϭ 4), and ϳ1 h for L1373R (n ϭ 2). C: effect of inhibitors on GFP-L1373R-ATP7B stability. At time 0, cells were harvested as described above or switched to medium containing the indicated inhibitors and harvested 4 h later. Proteins were analyzed as described in A (n ϭ 2). Ly, lysosomal inhibitors [leupeptin (250 M), pepstatin (10 g/ml), and E64d (10 g/ ml)]; Pr, proteasomal inhibitors [lactacystin (5 M) and MG132 (10 M)]. D: 4-phenylbutyric acid (PBA) increases the level of GFP-L1373P-ATP7B in WIF-B cells. Infected cells were left untreated (Ϫ) or treated (ϩ) with the reagent in basal medium for 24, fixed, stained with antilysosomal-associated membrane protein 1 (LAMP1), and imaged by confocal microscopy. Single confocal planes are shown. ‫,ء‬ apical space; arrow, lysosome.
shuttling to the lysosomes cannot be excluded. To explore the cellular mechanism(s) by which the L1373R mutant protein was being degraded, we treated infected cells for 4 h with only cycloheximide (the control) or additionally with inhibitors of proteasomes and/or lysosomes (Fig. 6C) . The amount of L1373R protein was decreased by ϳ80% after 4 h in the protein synthesis inhibitor alone. Addition of the lysosomal or proteasomal inhibitors resulted in smaller decreases, 70% and 50%, respectively, suggesting that both mechanisms contributed to the accelerated degradation of L1373R; results of using both types of inhibitors were additive (Fig. 6C) . Treatment of WIF-B cells infected with the L1373P mutant with these inhibitors showed similar trends (data not shown).
There is substantial documentation on the efficacy of chemical chaperones in stabilizing mutant membrane proteins (9, 21) and selected patient mutations of ATP7B (33) . Therefore, we tested the effect of the chaperone 4-phenylbutyric acid on L1373P and L1373R mutant proteins in the WIF-B hepatic cells. GFP-L1373P-ATP7B protein showed a clear increase in signal after 24 h. However, drug treatment resulted in substantial overlap of the mutant protein signal with the lysosomal marker (Fig. 6D) , suggesting accumulation of the protein in lysosomes. We observed a more modest increase for the L1373R mutant and only after 48 h of treatment (data not shown). These studies demonstrate that the conserved region adjacent to transmembrane domain 8 plays important roles in Golgi retention and protein stability of ATP7B.
DISCUSSION
In this study, we used a mutational approach to examine the role(s) of the COOH terminus in expression of ATP7B, Cutransport activity, and copper-responsive trafficking in polarized WIF-B cells and Menkes-null fibroblasts. Our results clearly demonstrate that this domain confers a higher copper sensitivity to ATP7B than to its cousin, ATP7A. There are also two regions of the COOH terminus of ATP7B that contribute to distinct aspects of its function in cells. The first is the boundary of transmembrane domain 8 and the beginning of the COOH terminus, a highly conserved sequence in both CuATPases of many species. When the leucine residue at position 1373 in this region of human ATP7B is mutated to proline or arginine, the resulting protein fails to be retained in the TGN in low copper and is degraded rapidly by a combination of lysosomal and proteasomal mechanisms. Treatment with a molecular chaperone stabilizes the proteins to some extent. The second region is at the distal end of the COOH terminus and contains a triL motif (L1453-56) that others have identified as important in the retrieval of ATP7B from its dispersed vesicular localization in elevated Cu to the Golgi when copper levels are lowered (8) . A surprising finding was the apparent absence of function for the middle of the 95-amino acid COOH terminus of ATP7B. Taken together, our results raise several important questions. For example, how does substitution of the ATP7A COOH terminus onto ATP7B lower the latter's sensitivity to copper? How does L1373 contribute to ATP7B protein stability and TGN retention? What is the function(s) of the 79-amino acid sequence between L1373 and the triL (1454 -1456)? Finally, what about the four missense ATP7B proteins that exhibited wild-type behavior in our assays? Are they Wilson disease-causing mutations? Fig. 7 . Trafficking behavior of GFP-L1373R-ATP7B. WIF-B cells were infected with GFP-L1373P-ATP7B adenovirus, cultured overnight in 10 M BCS, and then kept in 10 M BCS (A and A=) or incubated in 10 M CuCl2 (B and B=) for 1 h, fixed, stained with antibodies to aminopeptidase N (blue) and TGN38 (red), and imaged by confocal microscopy. Single confocal planes are shown. Exogenous GFP-L1373P-ATP7B is not retained in the Golgi in presence or absence of copper and is found in the apical region and membrane. Green haze in expressing cells is likely due to the protein's presence in the endoplasmic reticulum (see Supplemental Fig. S2 ). n, Nucleus; ‫,ء‬ apical space; arrow, apical membrane.
How Does Substitution of the ATP7A COOH Terminus Onto ATP7B Alter the Latter's Response to Copper?
In this study, we confirmed that the ATP7A COOH terminus contains information for targeting an GFP-ATP7B(L1373)7A chimera to the basolateral membrane in high copper and returning it to the TGN in low copper. Furthermore, we conclude that the apical targeting signal in the ATP7B NH 2 terminus and the basolateral signal in ATP7A were correctly read by cellular machinery, since the chimera was found in both membrane domains of the polarized hepatic cell (Fig. 4) . Our observation that the ATP7A COOH terminus confers lower Cu(I) sensitivity to GFP-wtATP7A and GFP-wtATP7B when the latter's COOH terminus is replaced with that of ATP7A was unexpected. However, ours is the first study in which copper-dependent trafficking of the two Cu-ATPases has been examined in the same polarized cell type. What might the ATP7A COOH terminus be doing? One possibility is that it, but not (or to a lesser extent) the ATP7B COOH terminus, regulates access of Cu(I) to key intramolecular binding site(s) present in ATP7A and ATP7B. The NH 2 -terminal metalbinding domains and/or the intramembranous sites in transmembrane domains 6, 7, and/or 8 are the obvious possibilities. Such COOH terminus-specific regulation would require protein-protein interactions, which, to our knowledge, have not been reported. Alternatively, the COOH terminus of ATP7A might interact with a cellular protein that, in turn, regulates Cu(I) access to these sites. Finally, the COOH terminus of ATP7A might adopt a conformation greatly favoring Golgi retention, since we and others consistently find ATP7A in the Golgi at copper concentrations that deplete ATP7B from this compartment (8, 26) . Clearly, more work is required to solve this mystery.
L1373 Mutant Protein Phenotypes Implicate the ATP7B COOH Terminus in Golgi Retention
Results of a study using yeast complementation to explore the role of the COOH terminus in ATP7B function demonstrate that deletion of the entire domain from L1373 reduced the resulting protein's stability and, consequently, its copper-loading activity (15) . Addition of only three residues partially restored these features. Our results show that a single amino acid change at position 1373 in the context of the full-length COOH terminus leads to a similar protein phenotype. Through the use of inhibitors, we determined that the two unstable proteins were degraded by a combination of proteasomal and lysosomal activities. Furthermore, although prolonged treatment of WIF-B cells with 4-phenylbutyric acid increased the amount of L1373P protein accumulating in WIF-B cells, much of it was present in lysosomes. This finding indicates that such treatment of Wilson disease patients harboring this or similar mutations might not be effective in reversing copper overload in the liver.
The fact that a fraction of the newly synthesized L1373R/P mutant proteins was able to exit the ER but then was not retained in the Golgi suggests that the ATP7B COOH terminus is involved in the wild-type protein's localization to this compartment when copper levels are low. Another diseaseassociated mutation, N41S, also fails to localize to the Golgi in low or high copper and is part of a nine-amino acid sequence that we recently identified (5). Thus the NH 2 and COOH termini of ATP7B participate in TGN retention in low copper. How might this occur? One possibility is that they act independently but both are required. A second is that they interact with one another. There is biochemical evidence that the nucleotide-binding and large NH 2 -terminal domains of ATP7B interact in vitro (31) . Perhaps the COOH terminus, in its properly folded state, might interact with the NH 2 -terminal domain as well. Along these lines, it seems reasonable that the Golgi retention function might extend into transmembrane domains 7 and 8, given that alignment of ATP7B from seven mammalian species shows high conservation from amino acid 1323 to 1379 (see Supplemental Fig. S5 ). Structural studies are needed to further investigate these possibilities.
Importantly and in contrast to GFP-N41S-ATP7B, the escaped GFP-L1373R/P-ATP7B proteins were found in the apical region and membrane of polarized WIF-B cells (Fig. 2,  E-H) , whereas the N41S mutant mislocalized to the basolateral membrane. This difference in trafficking suggests that the apical targeting signal in the NH 2 terminus was still active in the L1373R/P mutants.
Does the Middle Region of the ATP7B COOH Terminus Contribute to TGN Retention?
We were surprised to observe similar trafficking phenotypes between the COOH-terminal ATP7B truncation mutants, including GFP-Q1399Rfs-ATP7B, which lacks two-thirds of the COOH terminus (see Supplemental Table S1 ), and GFPtriLϾA-ATP7B in every assay. That is, the truncated mutant proteins exhibited Golgi retention deficiencies in low copper (BCS), as did the GFP-triLϾA-ATP7B construct, and failed to return to the Golgi when cells were shifted from 10 M CuCl 2 to 10 M BCS. Interestingly, the extent of the BCS phenotype (i.e., signal outside the Golgi) varied considerably between experiments, but within each experiment, GFP-Q1399Rfs-ATP7B consistently showed more punctae outside the Golgi than did GFP-triLϾA-ATP7B. Unfortunately, because of the variability and close relationship of the punctae to the Golgi, it was difficult to quantify these differences. Nonetheless, this result suggests that the middle region of the ATP7B COOH terminus might contribute to Golgi retention. In this context, it is interesting to note the presence of 13 S/T/Y residues after the Q1339R fs mutation; perhaps phosphorylation contributes to Golgi retention. Alternatively, the retention deficiency could reflect the capacity of ATP7B to exit its Golgi subcompartment, even in the presence of BCS, but fail to return due to absence of the triL signal.
Are All the Mutants Studied Here Wilson Disease-Causing Mutations?
Our study shows that the three different COOH-terminal truncation mutations result in proteins that cannot return to the Golgi upon lowering of cellular copper levels. This finding is significant relative to the trafficking phenotype of ATP7B but does not explain how lack of return to the Golgi causes disease, particularly since the triLϾA protein, which behaved similarly to these truncated proteins, reportedly accumulates and exports copper from cells (8) . Nonetheless, there is support for each truncation mutation causing Wilson disease (see Supplemental  Table S2 ).
What about the six COOH-terminal missense mutations? As discussed above, the aberrant phenotypes of the L1373P/R mutant proteins are strong evidence for their causing disease. In contrast, the remaining four, C1375S, P1379S, T1434M, and X1466R, showed no dramatic defects in copper transport, protein stability, or copper-responsive trafficking. Additionally, incomplete control information in the Wilson Disease Patient Mutation Database for the first two suggest that they are not disease-causing mutations (see Supplemental Table S2 ).
The normal protein phenotypes of T1434M and X1466R that we observed in this study are more difficult to reconcile with their clear disease-causing status (see Supplemental  Table S2 ). What might account for the apparently contradictory findings? The most obvious is that we are lacking a crucial test of ATP7B function that is defective in these proteins. Also plausible is that the Wilson disease patients carry an additional, deleterious mutation(s). In fact, one patient was identified as compound homozygous for T1434M and N1270S. Thus, although T1434M and X1466R exhibited wild-type trafficking (present study and Ref. 16 , respectively), N1270S was unable to functionally complement the yeast ccc2 deletion strain (19) . Perhaps cosegregation of T1434M with N1270S or another variant leads to disease in some individuals. Further sequence studies might clarify this issue.
Several other studies have reported wild-type behavior in proteins with putative disease-causing mutations (10, 15, 16) . Could these variations only affect ATP7B function in the context of another sequence variation? Supporting this proposal is the large number (ϳ139) of normal ATP7B sequence variations that have been identified (20) . Thus the combination of the background genotype and the putative disease-causing mutation may contribute to disease. Unfortunately, most reports do not provide supporting information for designating a specific variation as disease-causing or identify the mutation on the other chromosome. With the list of ATP7B sequence variations growing, more consistent and complete sequence information could guide protein studies and genotype-phenotype correlations.
